{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:50Z","timestamp":1786982750433,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011009","name":"International Society of Oncology Pharmacy Practitioners","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40261-025-01489-w","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:02:18Z","timestamp":1761544938000},"page":"945-956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-5427","authenticated-orcid":false,"given":"Sarah","family":"Glewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4095-8590","authenticated-orcid":false,"given":"Mussab","family":"Fagery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Lingaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Tie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5788-5805","authenticated-orcid":false,"given":"Maarten","family":"IJzerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5782-7912","authenticated-orcid":false,"given":"Marliese","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"12","key":"1489_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70083","volume":"17","author":"S Glewis","year":"2024","unstructured":"Glewis S, Lingaratnam S, Lee B, Campbell I, IJzerman M, Fagery M, et al. Pharmacogenetic-guided dosing for fluoropyrimidine ( DPYD ) and irinotecan ( UGT1A1*28) chemotherapies for patients with cancer ( PACIFIC - PGx ): a multicenter clinical trial. Clin Transl Sci. 2024;17(12):e70083.","journal-title":"Clin Transl Sci"},{"issue":"12","key":"1489_CR2","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist. 2021;26(12):1008\u201316.","journal-title":"Oncologist"},{"issue":"3","key":"1489_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD * 2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34(3):227\u201334.","journal-title":"J Clin Oncol"},{"key":"1489_CR4","doi-asserted-by":"crossref","unstructured":"White C, Paul C, Liet E, Kalpage D, Mossman D, Ziolkowski A, et al. Feasibility of DPYD genotyping in Australian Cancer Patients [Internet]. 2023. Available from: https:\/\/www.researchsquare.com\/article\/rs-2838793\/v1. Accessed 10 Sep 2024.","DOI":"10.21203\/rs.3.rs-2838793\/v1"},{"key":"1489_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2018.11.010","volume":"107","author":"LM Henricks","year":"2019","unstructured":"Henricks LM, Lunenburg CATC, De Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. A cost analysis of upfront DPYD genotype\u2013guided dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer. 2019;107:60\u20137.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1489_CR6","first-page":"e189","volume":"21","author":"GA Brooks","year":"2022","unstructured":"Brooks GA, Tapp S, Daly AT, Busam JA, Tosteson ANA. Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based adjuvant chemotherapy for colon cancer. Clin Colorectal Cancer. 2022;21(3):e189\u201395.","journal-title":"Clin Colorectal Cancer"},{"issue":"14","key":"1489_CR7","first-page":"1","volume":"21","author":"Ontario Health (Quality)","year":"2021","unstructured":"Ontario Health (Quality). DPYD genotyping in patients who have planned cancer treatment with fluoropyrimidines: a health technology assessment. Ont Health Technol Assess Ser. 2021;21(14):1\u2013186.","journal-title":"Ont Health Technol Assess Ser."},{"issue":"41","key":"1489_CR8","first-page":"JCO2202780","volume":"28","author":"J Knikman","year":"2023","unstructured":"Knikman J, Wilting T, Lopez-Yurda M, Henricks L, Lunenburg C, Man F, et al. Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy-a matched-pair analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2023;28(41):JCO2202780.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"9","key":"1489_CR9","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/ijc.32022","volume":"144","author":"LM Henricks","year":"2019","unstructured":"Henricks LM, van Merendonk LN, Meulendijks D, et al. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis. Int J Cancer. 2019;144(9):2347\u201354.","journal-title":"Int J Cancer"},{"issue":"4","key":"1489_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","volume":"28","author":"CATC Lunenburg","year":"2020","unstructured":"Lunenburg CATC, Van Der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, De Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28(4):508\u201317.","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"1489_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1489_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40261-024-01413-8","volume":"45","author":"D Abushanab","year":"2025","unstructured":"Abushanab D, Mohamed S, Abdel-latif R, Moustafa DA, Marridi W, Elazzazy S, et al. Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. A cost-effectiveness analysis. Clin Drug Investig. 2025;45(3):151\u201363.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"1489_CR13","doi-asserted-by":"publisher","first-page":"155932581880304","DOI":"10.1177\/1559325818803042","volume":"16","author":"C Murphy","year":"2018","unstructured":"Murphy C, Byrne S, Ahmed G, Kenny A, Gallagher J, Harvey H, et al. Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: a single-institution experience. Dose-Response. 2018;16(4):155932581880304.","journal-title":"Dose-Response"},{"issue":"1","key":"1489_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/10781552231167554","volume":"30","author":"S Glewis","year":"2024","unstructured":"Glewis S, Lingaratnam S, Krishnasamy M, Martin JH, Tie J, Alexander M, Michael M. Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: perspectives of medical oncologists and oncology pharmacists. J Oncol Pharm Pract. 2024;30(1):30\u20137. https:\/\/doi.org\/10.1177\/10781552231167554.","journal-title":"J Oncol Pharm Pract."},{"issue":"12","key":"1489_CR15","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1111\/cts.13664","volume":"16","author":"S Glewis","year":"2023","unstructured":"Glewis S, Krishnasamy M, Lingaratnam S, Harris S, Underhill C, Georgiou C, et al. Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey. Clin Transl Sci. 2023;16(12):2700\u20138.","journal-title":"Clin Transl Sci"},{"issue":"9","key":"1489_CR16","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1080\/0284186X.2022.2109423","volume":"61","author":"S Glewis","year":"2022","unstructured":"Glewis S, Alexander M, Lingaratnam S, Lee B, Campbell I, Krishnasamy M, et al. Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial. Acta Oncol. 2022;61(9):1136\u20139.","journal-title":"Acta Oncol"},{"issue":"1","key":"1489_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23.","journal-title":"BMC Med"},{"issue":"3","key":"1489_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/ijc.29025","volume":"136","author":"TK Froehlich","year":"2015","unstructured":"Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiad\u00e8r CR. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer. 2015;136(3):730\u20139.","journal-title":"Int J Cancer"},{"key":"1489_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2018.07.138","volume":"104","author":"CATC Lunenburg","year":"2018","unstructured":"Lunenburg CATC, Henricks LM, Dreussi E, Peters FP, Fiocco M, Meulendijks D, et al. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. Eur J Cancer. 2018;104:210\u20138.","journal-title":"Eur J Cancer"},{"issue":"16","key":"1489_CR20","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639\u201350.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1489_CR21","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/cpt.1257","volume":"105","author":"G Toffoli","year":"2019","unstructured":"Toffoli G, Innocenti F, Polesel J, De Mattia E, Sartor F, Dalle Fratte C, et al. The genotype for DPYD risk variants in patients with colorectal cancer and the related toxicity management costs in clinical practice. Clin Pharmacol Ther. 2019;105(4):994\u20131002.","journal-title":"Clin Pharmacol Ther"},{"key":"1489_CR22","unstructured":"TreeAge Software. TreeAge Pro 2024. Williamstown, MA. 2024. Available online: https:\/\/www.treeage.com. Accessed 1 Oct 2024."},{"issue":"11","key":"1489_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2217\/pgs.15.70","volume":"16","author":"LM Henricks","year":"2015","unstructured":"Henricks LM, Lunenburg CA, Meulendijks D, Gelderblom H, Cats A, Swen JJ. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16(11):1277\u201386.","journal-title":"Pharmacogenomics"},{"key":"1489_CR24","unstructured":"Pharmaceutical Benefits Scheme. Pharmaceutical Benefits Scheme (PBS) home [Internet]. Canberra: Australian Government Department of Health; 2023. Available from: https:\/\/www.pbs.gov.au\/pbs\/home. Accessed 1 June 2023."},{"key":"1489_CR25","unstructured":"Independent Hospital Pricing Authority. National Hospital Cost Data Collection (NHCDC): Public Sector 2022-23 [Internet]. 2023 [updated 2023]. Available from: https:\/\/www.ihacpa.gov.au\/resources\/national-hospital-cost-data-collection-nhcdc-public-sector-2022-23. Accessed 1 June 2023."},{"issue":"1","key":"1489_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-018-1013-9","volume":"16","author":"EM Stein","year":"2018","unstructured":"Stein EM, Yang M, Guerin A, Gao W, Galebach P, Xiang CQ, et al. Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States. Health Qual Life Outcomes. 2018;16(1):193.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"1489_CR27","first-page":"39","volume":"2","author":"S Hudgens","year":"2016","unstructured":"Hudgens S, Briggs A, Forsythe A, Tremblay G, Lloyd AJ. A method of deriving estimates of health state utilities for patients with metastatic breast cancer. J Clin Pathways. 2016;2(5):39\u201345.","journal-title":"J Clin Pathways."},{"issue":"6","key":"1489_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683\u201390.","journal-title":"Br J Cancer"},{"issue":"1","key":"1489_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6(1):84.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1489_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/jgs.12595","volume":"62","author":"WB Van Den Hout","year":"2014","unstructured":"Van Den Hout WB, Caljouw MAA, Putter H, Cools HJM, Gussekloo J. Cost-effectiveness of cranberry capsules to prevent urinary tract infection in long-term care facilities: economic evaluation with a randomized controlled trial. J Am Geriatr Soc. 2014;62(1):111\u20136.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"1489_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40273-017-0580-7","volume":"36","author":"Y Hagiwara","year":"2018","unstructured":"Hagiwara Y, Shiroiwa T, Shimozuma K, Kawahara T, Uemura Y, Watanabe T, et al. Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the SELECT BC study. Pharmacoeconomics. 2018;36(2):215\u201323.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1489_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2217\/pme-2022-0099","volume":"20","author":"R Koleva-Kolarova","year":"2023","unstructured":"Koleva-Kolarova R, Vellekoop H, Huygens S, Versteegh M, van M\u00f6lken MR, Szilberhorn L, et al. Cost\u2013effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK. Pers Med. 2023;20(4):339\u201355.","journal-title":"Pers Med"},{"key":"1489_CR33","unstructured":"Global currency conversions & money transfers. 1 EUR to AUD - Convert Euros to Australian Dollars [internet]. Global currency conversions & money transfers; 2024. Available from: 1 EUR to AUD - Euros to Australian Dollars Exchange Rate (xe.com). Accessed 1 July 2024."},{"key":"1489_CR34","unstructured":"Henricks LM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis."},{"key":"1489_CR35","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1200\/PO.20.00067","volume":"4","author":"RC Ly","year":"2020","unstructured":"Ly RC, Schmidt RE, Kiel PJ, Pratt VM, Schneider BP, Radovich M, et al. Severe capecitabine toxicity associated with a rare DPYD variant identified through whole-genome sequencing. JCO Precis Oncol. 2020;4:632\u20138.","journal-title":"JCO Precis Oncol"},{"issue":"22","key":"1489_CR36","doi-asserted-by":"publisher","first-page":"13923","DOI":"10.3390\/ijms232213923","volume":"23","author":"O De Luca","year":"2022","unstructured":"De Luca O, Salerno G, De Bernardini D, Torre MS, Simmaco M, Lionetto L, et al. Predicting dihydropyrimidine dehydrogenase deficiency and related 5-fluorouracil toxicity: opportunities and challenges of DPYD exon sequencing and the role of phenotyping assays. Int J Mol Sci. 2022;23(22):13923.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1489_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14796694.2024.2430725","volume":"21","author":"A Hussain","year":"2025","unstructured":"Hussain A, Szamreta E, Ning N, Kaminski A, Shah R, Aggarwal J, et al. Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey. Future Oncol. 2025;21(2):231\u20139.","journal-title":"Future Oncol"},{"issue":"35","key":"1489_CR38","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1080\/14796694.2024.2390821","volume":"20","author":"A Ferreira-Gonzalez","year":"2024","unstructured":"Ferreira-Gonzalez A, Ko G, Fusco N, Stewart F, Kistler K, Appukkuttan S, et al. Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review. Future Oncol. 2024;20(35):2765\u201377.","journal-title":"Future Oncol"},{"key":"1489_CR39","unstructured":"Cancer Institute NSW \/ eviQ. Dihydropyrimidine dehydrogenase (DPD) enzyme deficiency [Internet]. 1744-DPD enzyme deficiency, Clinical resources; endorsed v.6; last reviewed 24 Feb 2023. Available from: https:\/\/www.eviq.org.au\/clinical\u2011resources\/side\u2011effect\u2011and\u2011toxicity\u2011management\/prophylaxis\u2011and\u2011treatment\/1744\u2011dihydropyrimidine\u2011dehydrogenase\u2011dpd\u2011enzyme. Accessed 31 July 2025."},{"key":"1489_CR40","unstructured":"Medical Services Advisory Committee. DPYD genotyping to predict fluoropyrimidine\u2011induced toxicity: Public summary document, Application No.\u202f1760 [Internet]. Canberra: MSAC; considered 28\u201329 November 2024; released November\u202f2024. Available from: https:\/\/www.msac.gov.au\/sites\/default\/files\/2025-02\/1760_final_psd_-_nov2024.pdf. Accessed 31 July 2025."},{"key":"1489_CR41","unstructured":"Department of Health, Disability and Ageing. 1 November 2025 MBS pathology changes [Internet]. Canberra (AU): Medicare Benefits Schedule Online; 2025. Available from: https:\/\/www.mbsonline.gov.au\/internet\/mbsonline\/publishing.nsf\/Content\/Factsheet-1+November+2025+MBS+pathology+changes. Accessed 31 July 2025."},{"issue":"4","key":"1489_CR42","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/cts.12981","volume":"14","author":"TJ Wigle","year":"2021","unstructured":"Wigle TJ, Povitz BL, Medwid S, Teft WA, Legan RM, Lenehan J, et al. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. Clin Transl Sci. 2021;14(4):1338\u201348.","journal-title":"Clin Transl Sci"},{"issue":"9","key":"1489_CR43","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/imj.16463","volume":"54","author":"C White","year":"2024","unstructured":"White C, Kendall G, Millington T, Corcoran B, Paul C, Scott RJ, et al. Evaluation of early fluoropyrimidine toxicity in solid organ cancer patients: a retrospective observational study in Australia. Intern Med J. 2024;54(9):1506\u201314.","journal-title":"Intern Med J"},{"key":"1489_CR44","unstructured":"IHACPA. National Efficient Price Determination 2023\u201324 [internet]. Sydney NSW (AU): IHACPA; 2023. Available from: https:\/\/www.ihacpa.gov.au\/resources\/national-efficient-price-determination-2023-24. Accessed 12 June 2025."},{"key":"1489_CR45","unstructured":"Australian Government Department of Health and Aged Care. Medicare Benefits Schedule Online [Internet]. Australia (AU): Australian Government; 2024 [updated 2024]. Available from: https:\/\/www.mbsonline.gov.au\/. Accessed 1 June 2023."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01489-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01489-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01489-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:05:33Z","timestamp":1764594333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01489-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01489-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no direct conflict of interest related to the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest:"}},{"value":"The study was approved by the Peter MacCallum Cancer Centre Human Research Ethics Committee (HREC\/66681\/PMCC-2020). The study was performed in accordance with the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained by the study investigators from each participant or guardian.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All data generated or analysed during this study are included in this published article (and its supplementary information files).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data"}},{"value":"SG, MM, MA, MJ and MF designed the research, performed the research, analysed the data, wrote the manuscript, and provided the original draft and conceptualization. SG, MF, SL, SH, CG, CU, MW, RC, JHM, JT, MJ, MA and MM carried out writing, review, editing and conceptualisation. MF developed the model in TreeAge Pro, and all authors reviewed and validated the model structure. All authors had full access to all the data in this study. All authors read and approved the final version and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}